- Corcept Therapeutics Incorporated is working to improve on Korlym, its cortisol regulator and sole source of its $350 million plus top line, with next-generation relacorilant.
- In addition to Cushing’s Syndrome, relacorilant has demonstrated statistically significant efficacy in combination with chemotherapy in the treatment of ovarian cancer, prompting a pivotal trial.
- With exogenous threats to Korlym, multiple shots on goals from other cortisol regulator candidates, and insider buying, Corcept merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Checking In On Corcept Therapeutics